A MULTIPART, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT-450/R/ABT-267 WITH AND WITHOUT ABT-333 COADMINISTERED WITH AND WITHOUT RIBAVIRIN IN ADULT WITH GENOTYPE 1 OR 4 HEPATITIS C VIRUS (HCV) INFECTION AND HUMAN IMMUNODEFICIENCY VIRUS, TYPE 1 COINFECTION: